62:@0.092505:0.957873:0.109687:0.957873:0.109687:0.938882:0.092505:0.938882:0.008591:0.008591
3:@0.038824:0.310836:0.060302:0.310836:0.060302:0.263358:0.038824:0.263358:0.021478
CHAPTER 3:@0.117647:0.067219:0.190423:0.067219:0.190423:0.047140:0.117647:0.047140:0.009172:0.009650:0.008799:0.008861:0.007388:0.007906:0.009359:0.003320:0.008321
Introduction:@0.117647:0.126494:0.256049:0.126494:0.256049:0.098384:0.117647:0.098384:0.006217:0.013626:0.010343:0.012928:0.013132:0.013103:0.013015:0.012722:0.010343:0.006217:0.013132:0.013626
Epithelial ovarian cancer (OC) is characterized by the development of chemotherapy :@0.117647:0.168344:0.857073:0.168344:0.857073:0.147971:0.117647:0.147971:0.011505:0.011071:0.005273:0.006620:0.011299:0.008948:0.005250:0.005798:0.009405:0.005250:0.006574:0.010866:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.006574:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.006574:0.006939:0.016775:0.014678:0.006939:0.006574:0.005615:0.007670:0.006574:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.009108:0.011391:0.006574:0.010843:0.009724:0.006574:0.006620:0.011299:0.009039:0.006574:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011071:0.017485:0.009039:0.011391:0.006437:0.006574:0.010843:0.006209:0.006574:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.009724:0.004109
resistance and poor survival. Overall survival for patients with OC has only slightly im-:@0.117647:0.188923:0.852941:0.188923:0.852941:0.168550:0.117647:0.168550:0.007442:0.009039:0.007601:0.005615:0.007510:0.006551:0.009085:0.011596:0.008994:0.009039:0.004497:0.009085:0.011596:0.011391:0.004497:0.011502:0.011276:0.010843:0.007807:0.004497:0.007510:0.011413:0.008398:0.009838:0.005547:0.009838:0.009405:0.004976:0.004497:0.004497:0.016892:0.009633:0.009039:0.007898:0.009405:0.005387:0.005250:0.004497:0.007510:0.011413:0.008400:0.009838:0.005547:0.009838:0.009405:0.005250:0.004497:0.006026:0.010843:0.007807:0.004497:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.014723:0.005273:0.006620:0.011459:0.004497:0.016778:0.014678:0.004497:0.011391:0.009291:0.007670:0.004497:0.010843:0.011870:0.005182:0.009724:0.004497:0.007556:0.005250:0.005615:0.009930:0.011094:0.006620:0.005182:0.009724:0.004497:0.005615:0.017739:0.007533
proved over the past decades, despite developments in the field such as optimized surgical :@0.117647:0.209502:0.857029:0.209502:0.857029:0.189129:0.117647:0.189129:0.011071:0.007442:0.010866:0.009633:0.009108:0.011391:0.002945:0.010866:0.009633:0.009039:0.007807:0.002945:0.006620:0.011299:0.009039:0.002945:0.011368:0.009291:0.007510:0.006437:0.002945:0.011322:0.009108:0.009108:0.009291:0.011322:0.009039:0.007670:0.004497:0.002945:0.011322:0.009039:0.007510:0.011071:0.005273:0.006209:0.009039:0.002945:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011071:0.017485:0.009039:0.011391:0.006437:0.007670:0.002945:0.005615:0.011756:0.002945:0.006620:0.011299:0.009039:0.002945:0.005684:0.005615:0.008948:0.005182:0.011391:0.002945:0.007510:0.011345:0.008765:0.011459:0.002945:0.009291:0.007670:0.002945:0.010820:0.011048:0.006437:0.005615:0.017645:0.005615:0.008834:0.009108:0.011391:0.002945:0.007512:0.011413:0.007624:0.009861:0.005545:0.009108:0.009405:0.005250:0.004109
tumor resection, administration of (hyperthermic) intraperitoneal chemotherapy and :@0.117647:0.230080:0.857050:0.230080:0.857050:0.209707:0.117647:0.209707:0.006163:0.011413:0.017485:0.010843:0.007807:0.006551:0.007442:0.009039:0.007875:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.004497:0.006551:0.009291:0.011391:0.017645:0.005615:0.011756:0.005615:0.007510:0.006437:0.007898:0.008811:0.006437:0.005547:0.010843:0.011756:0.006551:0.010843:0.006209:0.006551:0.006939:0.011071:0.009724:0.011505:0.009039:0.007964:0.006620:0.011302:0.009039:0.007807:0.017645:0.005545:0.008994:0.006939:0.006551:0.005615:0.011391:0.006437:0.007898:0.008811:0.011505:0.009039:0.007807:0.005273:0.006209:0.010843:0.011596:0.009291:0.009405:0.005250:0.006551:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.009724:0.006551:0.009085:0.011596:0.011391:0.004109
introduction of targeted treatments such as PARP-inhibitors . While most patients with :@0.117647:0.250659:0.857046:0.250659:0.857046:0.230286:0.117647:0.230286:0.005615:0.011391:0.006437:0.007442:0.011276:0.011048:0.011345:0.009108:0.006437:0.005547:0.010843:0.011756:0.003310:0.010843:0.006209:0.003310:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.003310:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.007670:0.003310:0.007510:0.011345:0.008765:0.011459:0.003310:0.009291:0.007670:0.003310:0.010249:0.014929:0.013376:0.010592:0.007533:0.005615:0.011870:0.011459:0.005547:0.010820:0.005273:0.006209:0.010843:0.007624:0.007670:0.018253:0.004497:0.003310:0.020704:0.011459:0.005752:0.005182:0.009039:0.003310:0.017488:0.010957:0.007510:0.006437:0.003310:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.003310:0.014723:0.005273:0.006620:0.011459:0.004109
274:@0.617653:0.243043:0.635898:0.243043:0.635898:0.231166:0.617653:0.231166:0.006082:0.006082:0.006082
OC respond well to initial treatment, the majority will develop recurrent disease with-:@0.117647:0.271238:0.852941:0.271238:0.852941:0.250865:0.117647:0.250865:0.016778:0.014678:0.005399:0.007442:0.009039:0.007510:0.011505:0.010843:0.011596:0.011391:0.005399:0.014518:0.008948:0.005387:0.005250:0.005399:0.006209:0.011048:0.005399:0.005615:0.011756:0.005273:0.006437:0.005798:0.009402:0.005250:0.005410:0.006437:0.007442:0.009288:0.008813:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497:0.005399:0.006617:0.011302:0.009039:0.005399:0.017577:0.008811:0.005339:0.010845:0.007807:0.005271:0.006437:0.009724:0.005399:0.014723:0.005752:0.005387:0.005250:0.005399:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011276:0.005399:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005399:0.011391:0.005615:0.007875:0.009288:0.009291:0.007875:0.009039:0.005410:0.014723:0.005273:0.006620:0.011441:0.007533
in the first two years and become resistant to chemotherapy. In the setting of recurrent :@0.117647:0.291816:0.857166:0.291816:0.857166:0.271444:0.117647:0.271444:0.005615:0.011756:0.005227:0.006620:0.011299:0.009039:0.005227:0.005684:0.005684:0.007624:0.007510:0.006437:0.005227:0.006437:0.014518:0.011048:0.005227:0.009519:0.009291:0.009085:0.007624:0.007670:0.005227:0.009085:0.011596:0.011391:0.005227:0.011251:0.009108:0.008994:0.010843:0.017485:0.009039:0.005227:0.007442:0.009039:0.007601:0.005615:0.007510:0.006551:0.009085:0.011391:0.006437:0.005227:0.006209:0.011048:0.005227:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.007989:0.004497:0.005227:0.006894:0.011756:0.005227:0.006622:0.011299:0.009039:0.005227:0.007875:0.009131:0.006163:0.006437:0.005615:0.011459:0.009861:0.005227:0.010843:0.006209:0.005227:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.004109
disease, a wide range of chemotherapeutic and targeted drugs is available. PARP-inhibi-:@0.117647:0.312395:0.852941:0.312395:0.852941:0.292022:0.117647:0.292022:0.011391:0.005615:0.007875:0.009291:0.009291:0.007873:0.008743:0.004497:0.004360:0.009291:0.004360:0.014723:0.005547:0.011322:0.009039:0.004360:0.007898:0.009087:0.011459:0.009656:0.009039:0.004360:0.010843:0.006209:0.004360:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011505:0.009131:0.011071:0.006437:0.005547:0.008994:0.004360:0.009085:0.011596:0.011391:0.004360:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004360:0.011391:0.007964:0.011413:0.009724:0.007670:0.004360:0.005615:0.007670:0.004360:0.008925:0.009838:0.009087:0.005750:0.005433:0.009108:0.010911:0.005182:0.008743:0.004497:0.004360:0.010247:0.014929:0.013376:0.010592:0.007533:0.005615:0.011870:0.011459:0.005547:0.010820:0.005618:0.007533
tors are indicated for patients who experienced complete or partial response to previous :@0.117647:0.332974:0.857093:0.332974:0.857093:0.312601:0.117647:0.312601:0.006209:0.010843:0.007624:0.007670:0.004154:0.009085:0.007442:0.009039:0.004154:0.005615:0.011596:0.011391:0.005547:0.009108:0.008811:0.006209:0.009108:0.011391:0.004154:0.006026:0.010843:0.007807:0.004154:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004154:0.014792:0.011299:0.011048:0.004154:0.009108:0.010089:0.011505:0.009039:0.007807:0.005547:0.009039:0.011596:0.008994:0.009106:0.011391:0.004154:0.008994:0.010843:0.017280:0.011162:0.005182:0.009131:0.006209:0.009039:0.004154:0.010843:0.007807:0.004154:0.011365:0.009087:0.007964:0.006437:0.005798:0.009405:0.005250:0.004154:0.007444:0.009039:0.007510:0.011502:0.010845:0.011619:0.007873:0.009039:0.004154:0.006209:0.011048:0.004154:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007670:0.004109
platinum treatment, irrespective of :@0.117647:0.353553:0.415263:0.353553:0.415263:0.333180:0.117647:0.333180:0.011162:0.005433:0.008811:0.006437:0.005615:0.011391:0.011413:0.017645:0.004497:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497:0.004497:0.005615:0.007807:0.007442:0.009039:0.007510:0.011505:0.009108:0.009108:0.006437:0.005547:0.009633:0.009039:0.004497:0.010843:0.006209:0.004109
BRCA1/2-:@0.415647:0.354021:0.508735:0.354021:0.508735:0.331999:0.415647:0.331999:0.013217:0.013468:0.014495:0.015157:0.010888:0.007350:0.010888:0.007624
mutation status . Still, :@0.508734:0.353553:0.707834:0.353553:0.707834:0.333180:0.508734:0.333180:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.007510:0.006551:0.008811:0.006163:0.011413:0.007670:0.018244:0.004497:0.004497:0.009793:0.006437:0.005752:0.005387:0.004976:0.004497:0.004109
275:@0.639645:0.345937:0.657890:0.345937:0.657890:0.334059:0.639645:0.334059:0.006082:0.006082:0.006082
BRCA1/2:@0.708221:0.354021:0.793684:0.354021:0.793684:0.331999:0.708221:0.331999:0.013217:0.013468:0.014495:0.015157:0.010888:0.007350:0.010888
-muta-:@0.793683:0.353553:0.852941:0.353553:0.852941:0.333180:0.793683:0.333180:0.007533:0.017280:0.011071:0.006551:0.009290:0.007533
tion carriers experience more benefit from PARP-inhibition compared to patients with :@0.117647:0.374131:0.857050:0.374131:0.857050:0.353758:0.117647:0.353758:0.006437:0.005547:0.010843:0.011756:0.005033:0.009108:0.009085:0.007807:0.007807:0.005547:0.009039:0.007624:0.007670:0.005033:0.009108:0.010089:0.011505:0.009039:0.007807:0.005547:0.009039:0.011596:0.008994:0.009039:0.005033:0.017485:0.010843:0.007442:0.009039:0.005033:0.011254:0.009039:0.011596:0.009039:0.005684:0.005341:0.006437:0.005033:0.006414:0.007442:0.010843:0.017645:0.005033:0.010249:0.014929:0.013376:0.010592:0.007533:0.005615:0.011868:0.011459:0.005547:0.010820:0.005273:0.006437:0.005547:0.010843:0.011756:0.005033:0.008994:0.010843:0.017280:0.011368:0.009085:0.007442:0.009108:0.011391:0.005033:0.006209:0.011048:0.005033:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.005033:0.014723:0.005273:0.006620:0.011459:0.004109
homologous recombination (HR)-proficient tumors . However, for the majority of re-:@0.117647:0.394710:0.852941:0.394710:0.852941:0.374337:0.117647:0.374337:0.011299:0.010843:0.017485:0.010934:0.005182:0.011048:0.009656:0.010820:0.011413:0.007670:0.004565:0.007442:0.009108:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.004565:0.006939:0.016846:0.013376:0.006939:0.007533:0.011071:0.007442:0.010843:0.005684:0.005615:0.008994:0.005547:0.009039:0.011391:0.006437:0.004565:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.018265:0.004497:0.004565:0.016207:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.004565:0.006026:0.010843:0.007807:0.004565:0.006620:0.011299:0.009039:0.004565:0.017577:0.008811:0.005339:0.010843:0.007807:0.005273:0.006437:0.009724:0.004565:0.010843:0.006209:0.004565:0.007442:0.009081:0.007533
275:@0.557905:0.387094:0.576150:0.387094:0.576150:0.375216:0.557905:0.375216:0.006082:0.006082:0.006082
lapsed patients and drugs, no genetic markers are available to predict response. These :@0.117647:0.415289:0.857141:0.415289:0.857141:0.394916:0.117647:0.394916:0.005433:0.008811:0.011185:0.007875:0.009108:0.011391:0.006186:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.006186:0.009085:0.011596:0.011391:0.006186:0.011391:0.007967:0.011413:0.009724:0.007670:0.004497:0.006186:0.011596:0.011048:0.006186:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.006186:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.006186:0.009085:0.007442:0.009039:0.006186:0.008925:0.009838:0.009085:0.005752:0.005430:0.009108:0.010911:0.005184:0.009039:0.006186:0.006209:0.011048:0.006186:0.011071:0.007442:0.009108:0.011391:0.005547:0.009108:0.006437:0.006186:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.008743:0.004497:0.006186:0.011470:0.011311:0.009039:0.007873:0.009039:0.004109
patients might benefit from patient-derived model systems that can be employed to test :@0.117647:0.435867:0.856936:0.435867:0.856936:0.415494:0.117647:0.415494:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004451:0.017645:0.005615:0.009930:0.011094:0.006437:0.004451:0.011254:0.009039:0.011596:0.009039:0.005684:0.005341:0.006437:0.004451:0.006414:0.007442:0.010843:0.017645:0.004451:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.004451:0.017485:0.011276:0.011322:0.008948:0.005250:0.004451:0.007761:0.009724:0.007510:0.006209:0.009039:0.017508:0.007670:0.004451:0.006620:0.011391:0.008811:0.006437:0.004451:0.009108:0.009085:0.011756:0.004451:0.011251:0.009039:0.004451:0.009039:0.017280:0.011160:0.005184:0.010866:0.009519:0.009108:0.011391:0.004451:0.006209:0.011048:0.004451:0.006209:0.009039:0.007510:0.006437:0.004109
response to drugs prior to treatment in the clinic.:@0.117647:0.456446:0.528662:0.456446:0.528662:0.436073:0.117647:0.436073:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004109:0.006209:0.011048:0.004109:0.011391:0.007964:0.011413:0.009724:0.007670:0.004109:0.011071:0.007807:0.005547:0.010843:0.007807:0.004109:0.006209:0.011048:0.004109:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004109:0.005615:0.011756:0.004109:0.006620:0.011299:0.009039:0.004109:0.008765:0.005250:0.005615:0.011756:0.005545:0.008994:0.004497
Traditionally, OC drug response has been studied in 2D-cell lines and xenografts. 2D-cell :@0.117647:0.497603:0.856940:0.497603:0.856940:0.477231:0.117647:0.477231:0.011231:0.007898:0.009291:0.011391:0.005273:0.006437:0.005547:0.010843:0.011687:0.009405:0.005387:0.005182:0.007989:0.004497:0.003104:0.016778:0.014678:0.003104:0.011391:0.007967:0.011413:0.009861:0.003104:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.003104:0.011391:0.009291:0.007670:0.003104:0.011254:0.009108:0.009039:0.011756:0.003104:0.007510:0.006163:0.011345:0.011391:0.005547:0.009108:0.011391:0.003104:0.005615:0.011756:0.003104:0.010432:0.016139:0.007533:0.008994:0.008948:0.005387:0.005250:0.003104:0.005250:0.005615:0.011596:0.009039:0.007670:0.003104:0.009087:0.011596:0.011391:0.003104:0.009884:0.009039:0.011596:0.011048:0.009861:0.007898:0.009085:0.006197:0.006197:0.007670:0.004497:0.003104:0.010432:0.016139:0.007533:0.008994:0.008948:0.005387:0.005250:0.004109
lines offer a relatively cheap and quick model system, suitable for high-throughput drug :@0.117647:0.518182:0.857116:0.518182:0.857116:0.497809:0.117647:0.497809:0.005250:0.005615:0.011596:0.009039:0.007670:0.004383:0.010845:0.005969:0.005787:0.009039:0.007807:0.004383:0.009291:0.004383:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.009633:0.008948:0.005182:0.009724:0.004383:0.008765:0.011299:0.009291:0.008811:0.011276:0.004383:0.009085:0.011596:0.011391:0.004383:0.010703:0.011413:0.005547:0.008765:0.010523:0.004383:0.017485:0.011276:0.011322:0.008948:0.005250:0.004383:0.007759:0.009724:0.007512:0.006209:0.009039:0.017645:0.004497:0.004383:0.007510:0.011413:0.005273:0.006551:0.009108:0.010911:0.005182:0.009039:0.004383:0.006026:0.010843:0.007807:0.004383:0.011459:0.005615:0.009930:0.011459:0.007533:0.006617:0.011459:0.007442:0.010820:0.011413:0.009927:0.011094:0.011048:0.011071:0.006437:0.004383:0.011391:0.007967:0.011413:0.009861:0.004109
screening; while patient-derived xenografts offer the potential to study tumor drug re-:@0.117647:0.538761:0.852941:0.538761:0.852941:0.518388:0.117647:0.518388:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.004497:0.005501:0.014792:0.011459:0.005752:0.005182:0.009039:0.005501:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.005501:0.009884:0.009039:0.011596:0.011048:0.009861:0.007898:0.009085:0.006197:0.006197:0.007670:0.005501:0.010843:0.005969:0.005787:0.009039:0.007807:0.005501:0.006620:0.011299:0.009039:0.005501:0.011502:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.005501:0.006209:0.011048:0.005501:0.007510:0.006166:0.011345:0.011322:0.009724:0.005501:0.006163:0.011413:0.017485:0.010845:0.007807:0.005501:0.011391:0.007967:0.011413:0.009861:0.005501:0.007442:0.009128:0.007533
sponse in a living organism, but are not suitable for high-throughput drug screening :@0.117647:0.559340:0.856934:0.559340:0.856934:0.538967:0.117647:0.538967:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.006711:0.005615:0.011756:0.006711:0.009291:0.006711:0.005250:0.005547:0.009838:0.005615:0.011459:0.009861:0.006711:0.010843:0.007624:0.009861:0.009085:0.011756:0.005615:0.007601:0.017645:0.004497:0.006711:0.010797:0.011071:0.006437:0.006711:0.009085:0.007442:0.009039:0.006711:0.011596:0.010820:0.006437:0.006711:0.007510:0.011413:0.005273:0.006549:0.009108:0.010911:0.005182:0.009039:0.006711:0.006026:0.010843:0.007807:0.006711:0.011459:0.005615:0.009930:0.011459:0.007533:0.006617:0.011459:0.007442:0.010820:0.011413:0.009930:0.011094:0.011048:0.011071:0.006437:0.006711:0.011391:0.007967:0.011413:0.009861:0.006711:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.004109
experiments . In the past decade patient-derived organoids (PDOs) have been estab-:@0.117647:0.579918:0.852941:0.579918:0.852941:0.559545:0.117647:0.559545:0.009108:0.010089:0.011505:0.009039:0.007807:0.005615:0.017483:0.009039:0.011391:0.006437:0.007670:0.018246:0.004497:0.005615:0.006894:0.011756:0.005615:0.006620:0.011299:0.009039:0.005615:0.011368:0.009291:0.007510:0.006437:0.005615:0.011322:0.009108:0.009108:0.009291:0.011322:0.009039:0.005615:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.005615:0.010845:0.007624:0.009861:0.009083:0.011598:0.010843:0.005547:0.011391:0.007670:0.005615:0.006939:0.011664:0.016504:0.016253:0.007670:0.006939:0.005615:0.011391:0.008925:0.009633:0.009039:0.005615:0.011254:0.009108:0.009039:0.011756:0.005615:0.009039:0.007510:0.006551:0.009108:0.011084:0.007533
276:@0.222832:0.572302:0.241077:0.572302:0.241077:0.560425:0.222832:0.560425:0.006082:0.006082:0.006082
lished , a 3D-cell culture model system that maintains cellular heterogeneity of healthy :@0.117647:0.600497:0.857053:0.600497:0.857053:0.580124:0.117647:0.580124:0.005250:0.005615:0.007556:0.011299:0.009108:0.011391:0.018244:0.004497:0.004063:0.009291:0.004063:0.010432:0.016139:0.007533:0.008994:0.008948:0.005387:0.005250:0.004063:0.009108:0.011550:0.004908:0.006163:0.011413:0.007442:0.009039:0.004063:0.017483:0.011276:0.011322:0.008948:0.005250:0.004063:0.007761:0.009724:0.007510:0.006209:0.009039:0.017645:0.004063:0.006620:0.011391:0.008811:0.006437:0.004063:0.017577:0.009085:0.005615:0.011391:0.006551:0.009085:0.005615:0.011619:0.007670:0.004063:0.008994:0.008950:0.005385:0.004908:0.011550:0.005433:0.009085:0.007807:0.004063:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.004063:0.010843:0.006209:0.004063:0.011299:0.009291:0.009405:0.004905:0.006620:0.011071:0.009724:0.004109
277:@0.167865:0.592881:0.186111:0.592881:0.186111:0.581004:0.167865:0.581004:0.006082:0.006082:0.006082
tissues and tumors. Recently, PDOs of OC were established which represent the genom-:@0.117647:0.621076:0.852941:0.621076:0.852941:0.600703:0.117647:0.600703:0.006437:0.005615:0.007533:0.007510:0.011345:0.009039:0.007670:0.003972:0.009085:0.011596:0.011391:0.003972:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.004497:0.003972:0.013696:0.009106:0.008994:0.009039:0.011391:0.006620:0.005182:0.007989:0.004497:0.003972:0.011664:0.016504:0.016253:0.007670:0.003972:0.010843:0.006209:0.003972:0.016778:0.014678:0.003972:0.014518:0.009039:0.007442:0.009039:0.003972:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011299:0.009108:0.011391:0.003972:0.014792:0.011459:0.005547:0.008765:0.011459:0.003972:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.003972:0.006620:0.011299:0.009039:0.003972:0.009658:0.009039:0.011596:0.010843:0.017712:0.007533
ic features of the original tumors:@0.117647:0.641654:0.397296:0.641654:0.397296:0.621281:0.117647:0.621281:0.005547:0.008994:0.005593:0.006026:0.009291:0.008811:0.006163:0.011413:0.007442:0.009039:0.007670:0.005593:0.010843:0.006209:0.005593:0.006620:0.011299:0.009039:0.005593:0.010840:0.007807:0.005615:0.009861:0.005615:0.011687:0.009405:0.005250:0.005593:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670
278–280:@0.397288:0.634038:0.440659:0.634038:0.440659:0.622161:0.397288:0.622161:0.006082:0.006082:0.006082:0.006880:0.006082:0.006082:0.006082
. Furthermore, a drug screening comparison be-:@0.440657:0.641654:0.852941:0.641654:0.852941:0.621281:0.440657:0.621281:0.004497:0.005593:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.005593:0.009291:0.005593:0.011391:0.007967:0.011413:0.009861:0.005593:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.005593:0.008994:0.010843:0.017280:0.011368:0.009085:0.007807:0.005615:0.007875:0.010843:0.011756:0.005593:0.011254:0.009026:0.007533
tween 2D-cultures and PDOs of OC revealed that cytostatic drug efficacy was dependent :@0.117647:0.662233:0.856936:0.662233:0.856936:0.641860:0.117647:0.641860:0.006437:0.014518:0.009108:0.009039:0.011756:0.003287:0.010432:0.016139:0.007533:0.009108:0.011550:0.004905:0.006166:0.011413:0.007442:0.009039:0.007670:0.003287:0.009085:0.011596:0.011391:0.003287:0.011664:0.016504:0.016253:0.007670:0.003287:0.010843:0.006209:0.003287:0.016778:0.014678:0.003287:0.007442:0.009336:0.009633:0.009291:0.009405:0.005182:0.009108:0.011391:0.003287:0.006620:0.011391:0.008811:0.006437:0.003287:0.009382:0.009724:0.006209:0.010957:0.007510:0.006551:0.008811:0.006437:0.005547:0.008994:0.003287:0.011391:0.007967:0.011413:0.009861:0.003287:0.009039:0.005692:0.005692:0.005623:0.009108:0.009291:0.009382:0.009724:0.003287:0.014723:0.009291:0.007670:0.003287:0.011320:0.009131:0.011505:0.009039:0.011596:0.011322:0.009039:0.011391:0.006437:0.004109
on the employed culture system; PDO drug responses correlated better with genomic :@0.117647:0.682812:0.857141:0.682812:0.857141:0.662439:0.117647:0.662439:0.010843:0.011756:0.006049:0.006620:0.011299:0.009039:0.006049:0.009039:0.017280:0.011162:0.005182:0.010866:0.009519:0.009108:0.011391:0.006049:0.009108:0.011550:0.004908:0.006163:0.011413:0.007442:0.009039:0.006049:0.007761:0.009724:0.007510:0.006209:0.009039:0.017645:0.004497:0.006049:0.011662:0.016504:0.016412:0.006049:0.011391:0.007967:0.011413:0.009861:0.006049:0.007444:0.009039:0.007510:0.011502:0.010843:0.011621:0.007873:0.009039:0.007670:0.006049:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.006049:0.011254:0.009131:0.006163:0.006209:0.009039:0.007807:0.006049:0.014723:0.005273:0.006620:0.011459:0.006049:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004109
aberrations compared to 2D-cell cultures . To employ the organoid system to guide :@0.117647:0.703390:0.857066:0.703390:0.857066:0.683018:0.117647:0.683018:0.009108:0.011254:0.009039:0.007807:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.006597:0.008994:0.010843:0.017280:0.011368:0.009085:0.007442:0.009108:0.011391:0.006597:0.006211:0.011048:0.006597:0.010432:0.016139:0.007533:0.008994:0.008948:0.005387:0.005250:0.006597:0.009108:0.011550:0.004908:0.006163:0.011413:0.007442:0.009039:0.007670:0.018229:0.004497:0.006597:0.010866:0.011048:0.006597:0.009039:0.017280:0.011162:0.005182:0.010866:0.009724:0.006597:0.006620:0.011299:0.009039:0.006597:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.006597:0.007761:0.009724:0.007510:0.006209:0.009039:0.017645:0.006597:0.006209:0.011048:0.006597:0.009861:0.011413:0.005545:0.011322:0.009039:0.004109
280:@0.472796:0.695774:0.491041:0.695774:0.491041:0.683897:0.472796:0.683897:0.006082:0.006082:0.006082
treatment choice in the clinic, it is vital that the correlation between PDO drug response :@0.117647:0.723969:0.857009:0.723969:0.857009:0.703596:0.117647:0.703596:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004109:0.008768:0.011299:0.010843:0.005547:0.008994:0.009039:0.004109:0.005615:0.011756:0.004109:0.006620:0.011299:0.009039:0.004109:0.008765:0.005250:0.005615:0.011756:0.005547:0.008994:0.004497:0.004109:0.005273:0.006437:0.004109:0.005615:0.007670:0.004109:0.009838:0.005273:0.006551:0.009405:0.005250:0.004109:0.006620:0.011391:0.008811:0.006437:0.004109:0.006620:0.011302:0.009039:0.004109:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.004109:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.004109:0.011664:0.016501:0.016412:0.004109:0.011391:0.007967:0.011413:0.009861:0.004109:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004109
and clinical drug response is established. To this extent, prospective clinical trials have :@0.117647:0.744548:0.857162:0.744548:0.857162:0.724175:0.117647:0.724175:0.009085:0.011596:0.011391:0.005570:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.005570:0.011391:0.007964:0.011413:0.009861:0.005570:0.007442:0.009039:0.007512:0.011502:0.010843:0.011619:0.007875:0.009039:0.005570:0.005615:0.007670:0.005570:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011299:0.009108:0.011117:0.004497:0.005570:0.010866:0.011048:0.005570:0.006620:0.011459:0.005615:0.007670:0.005570:0.009106:0.010089:0.006209:0.009039:0.011391:0.006437:0.004497:0.005570:0.011071:0.007442:0.010957:0.007510:0.011505:0.009108:0.009108:0.006437:0.005547:0.009633:0.009039:0.005570:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.005570:0.006437:0.007807:0.005796:0.009405:0.005250:0.007670:0.005570:0.011391:0.008925:0.009635:0.009039:0.004109
been performed with PDOs of patients with colorectal cancer, in which :@0.117647:0.765127:0.736728:0.765127:0.736728:0.744754:0.117647:0.744754:0.011254:0.009108:0.009039:0.011756:0.006003:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.006003:0.014723:0.005273:0.006620:0.011459:0.006003:0.011662:0.016504:0.016253:0.007670:0.006003:0.010843:0.006209:0.006003:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.006003:0.014723:0.005271:0.006620:0.011459:0.006003:0.008994:0.010934:0.005182:0.010843:0.007442:0.009108:0.009108:0.006551:0.009405:0.005250:0.006003:0.009108:0.009085:0.011596:0.008994:0.009039:0.006255:0.004497:0.006003:0.005615:0.011756:0.006003:0.014792:0.011459:0.005547:0.008765:0.011459:0.004109
in vitro:@0.738708:0.765595:0.806298:0.765595:0.806298:0.743573:0.738708:0.743573:0.005935:0.012144:0.007647:0.010500:0.005912:0.006802:0.007921:0.010729
 drug :@0.806299:0.765127:0.857040:0.765127:0.857040:0.744754:0.806299:0.744754:0.006003:0.011391:0.007964:0.011413:0.009861:0.004109
screening recapitulated patient response to chemotherapy and targeted drugs:@0.117647:0.785705:0.774511:0.785705:0.774511:0.765332:0.117647:0.765332:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.005524:0.007442:0.009108:0.009108:0.008811:0.011071:0.005273:0.006163:0.011550:0.005433:0.008811:0.006209:0.009108:0.011391:0.005524:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.005524:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007875:0.009039:0.005524:0.006209:0.011048:0.005524:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.009724:0.005524:0.009085:0.011596:0.011391:0.005524:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.005524:0.011391:0.007967:0.011413:0.009724:0.007670
138,281:@0.774480:0.778089:0.813592:0.778089:0.813592:0.766212:0.774480:0.766212:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. For :@0.813591:0.785705:0.857051:0.785705:0.857051:0.765332:0.813591:0.765332:0.004497:0.005524:0.010683:0.010840:0.007807:0.004109
OC, we and others previously provided anecdotal evidence on the correlation between :@0.117647:0.806284:0.857075:0.806284:0.857075:0.785911:0.117647:0.785911:0.016778:0.014678:0.004497:0.005056:0.014518:0.009039:0.005068:0.009085:0.011596:0.011391:0.005056:0.010820:0.006620:0.011299:0.009039:0.007624:0.007670:0.005056:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.005068:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009108:0.011391:0.005056:0.009085:0.011596:0.009108:0.008994:0.011322:0.010820:0.006551:0.009405:0.005250:0.005056:0.009336:0.009838:0.005547:0.011322:0.009039:0.011596:0.008994:0.009039:0.005056:0.010843:0.011756:0.005068:0.006620:0.011299:0.009039:0.005056:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.005056:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.004109
clinical and PDO drug response:@0.117647:0.826863:0.386932:0.826863:0.386932:0.806490:0.117647:0.806490:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004109:0.009085:0.011596:0.011391:0.004109:0.011662:0.016504:0.016412:0.004109:0.011391:0.007967:0.011413:0.009861:0.004109:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039
278,279,282:@0.386931:0.819247:0.446911:0.819247:0.446911:0.807369:0.386931:0.807369:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
, but direct comparisons are still limited.:@0.446908:0.826863:0.783076:0.826863:0.783076:0.806490:0.446908:0.806490:0.004497:0.004109:0.010797:0.011071:0.006437:0.004109:0.011391:0.005615:0.007442:0.009106:0.009108:0.006437:0.004109:0.008994:0.010843:0.017280:0.011368:0.009085:0.007807:0.005615:0.007875:0.010843:0.011619:0.007670:0.004109:0.009085:0.007442:0.009039:0.004109:0.007510:0.006437:0.005752:0.005387:0.005250:0.004109:0.005250:0.005615:0.017645:0.005273:0.006209:0.009108:0.011117:0.004497
When predicting treatment response, genetic heterogeneity should be considered. Ep-:@0.117647:0.868020:0.852941:0.868020:0.852941:0.847647:0.117647:0.847647:0.020704:0.011299:0.009039:0.011756:0.005866:0.011071:0.007442:0.009108:0.011391:0.005547:0.009108:0.006437:0.005615:0.011459:0.009861:0.005866:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.005866:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.008743:0.004497:0.005866:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.005866:0.011302:0.009128:0.006211:0.009039:0.007442:0.011048:0.009653:0.009039:0.011598:0.009039:0.005271:0.006437:0.009724:0.005866:0.007556:0.011299:0.010820:0.011550:0.005182:0.011391:0.005866:0.011254:0.009039:0.005866:0.008994:0.010843:0.011619:0.007601:0.005547:0.011322:0.009039:0.007442:0.009108:0.011117:0.004497:0.005866:0.011507:0.011226:0.007533
ithelial OC, especially the high-grade serous subtype, is a heterogeneous disease with :@0.117647:0.888599:0.857048:0.888599:0.857048:0.868226:0.117647:0.868226:0.005273:0.006620:0.011299:0.008948:0.005250:0.005798:0.009405:0.005250:0.006378:0.016778:0.014678:0.004497:0.006380:0.009039:0.007510:0.011502:0.009108:0.008994:0.005798:0.009405:0.005387:0.005182:0.009724:0.006380:0.006620:0.011299:0.009039:0.006378:0.011459:0.005615:0.009930:0.011459:0.007533:0.009861:0.007898:0.009291:0.011322:0.009039:0.006378:0.007875:0.009039:0.007442:0.010820:0.011413:0.007670:0.006380:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.008743:0.004497:0.006380:0.005615:0.007670:0.006378:0.009291:0.006380:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009108:0.010820:0.011413:0.007670:0.006378:0.011391:0.005615:0.007875:0.009291:0.009291:0.007875:0.009039:0.006378:0.014723:0.005273:0.006620:0.011459:0.004109
widespread inter- and intrapatient genetic heterogeneity:@0.117647:0.909178:0.585916:0.909178:0.585916:0.888805:0.117647:0.888805:0.014723:0.005547:0.011322:0.009039:0.007510:0.011071:0.007442:0.009291:0.009291:0.011391:0.003607:0.005615:0.011391:0.006209:0.009039:0.007236:0.007533:0.003607:0.009085:0.011596:0.011391:0.003607:0.005615:0.011391:0.006437:0.007898:0.008811:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.003607:0.009656:0.009039:0.011598:0.009128:0.006437:0.005547:0.008994:0.003607:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724
78,283:@0.585957:0.901561:0.618987:0.901561:0.618987:0.889684:0.585957:0.889684:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. A virtue of the PDO model :@0.618986:0.909178:0.857001:0.909178:0.857001:0.888805:0.618986:0.888805:0.004497:0.003607:0.014929:0.003607:0.009838:0.005615:0.007967:0.006163:0.011345:0.009039:0.003607:0.010843:0.006209:0.003607:0.006620:0.011299:0.009039:0.003607:0.011664:0.016504:0.016412:0.003607:0.017485:0.011276:0.011322:0.008948:0.005250:0.004109